This inventor holds 1 USPTO granted patent and 4 published patent applications. Top assignee: Sk Chemicals Co., Ltd.. Active years: 2015.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2015
Title: The Innovative Mind of Joon-gyo Oh
Introduction
Joon-gyo Oh is a prominent inventor based in Suwon-si, South Korea. With a strong background in pharmaceutical innovations, he has dedicated his career to developing advanced compositions that enhance drug delivery methods. His contributions are well-illustrated through his patent in the field, which focuses on improving the stability of pharmaceutical compounds.
Latest Patents
Joon-gyo Oh holds a patent for a "Transdermal composition comprising tolterodine." This innovative transdermal composition boasts improved storage stability, primarily by incorporating an antioxidant to stabilize tolterodine. This significant advancement allows for the long-term storage of the composition, demonstrating its reliability and effectiveness in medical applications.
Career Highlights
Currently, Joon-gyo Oh works with SK Chemicals Co., Ltd., a reputable company in the chemical and pharmaceutical industry. His role there has allowed him to contribute to the development of cutting-edge products that enhance patient care and treatment options. His singular focus on innovation has made a meaningful impact within his field.
Collaborations
Throughout his career, Joon-gyo Oh has collaborated with talented professionals, including coworkers Yong Youn Hwang and Won Jae Choi. These collaborations have bolstered his research and development efforts, fostering an environment of creativity and shared expertise that has propelled innovative breakthroughs.
Conclusion
Joon-gyo Oh exemplifies the creativity and commitment of today’s inventors. His work on the transdermal composition demonstrates the potential for innovations in the pharmaceutical industry that can lead to enhanced patient outcomes. As he continues to push the boundaries of science, his future endeavors are eagerly anticipated by both peers and the industry as a whole.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
